Fresenius Kabi has stepped up its marketing of its Tyenne (tocilizumab-aazg) rival to Actemra in the US, introducing the country’s first subcutaneous tocilizumab biosimilar alongside the existing intravenous version that launched earlier this year.
Tyenne was approved in both SC and IV formulations by the US Food and Drug Administration earlier this year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?